Gerald W. DeVries
14Patents
3h-index
18Co-inventors
53Inventor score
Filing activity: Apr 30, 2007 → Dec 29, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8968766B2 | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods | Emerging Cross-Sectional Technologies | 19 | Active |
| US7749530B2 | Kinase inhibitors | Chemistry; Metallurgy | 4 | Active |
| US8591885B2 | Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems | Human Necessities | 4 | Active |
| US9233070B2 | Biodegradable intravitreal tyrosine kinase implants | Human Necessities | 3 | Active |
| US8455656B2 | Kinase inhibitors | Human Necessities | 2 | Active |
| US10076492B2 | Biodegradable intravitreal tyrosine kinase implants | Human Necessities | 2 | Active |
| US11400089B2 | Multikinase inhibitors and uses in reproductive and digestive tract fibrosis | Human Necessities | 1 | Active |
| US8143410B2 | Kinase inhibitors | Emerging Cross-Sectional Technologies | 1 | Active |
| US11078262B2 | High viscosity macromolecular compositions for treating ocular conditions | Chemistry; Metallurgy | 1 | Active |
| US11376252B2 | Multikinase inhibitors and uses in prostatic hyperplasia and urinary track diseases | Human Necessities | 1 | Active |
| US11278546B2 | Multikinase inhibitors and uses in ocular fibrosis | Human Necessities | 1 | Active |
| US8383825B2 | Kinase inhibitors | Emerging Cross-Sectional Technologies | 0 | Active |
| US10881608B2 | Biodegradable intravitreal tyrosine kinase implants | Human Necessities | 0 | Active |
| US12138252B2 | Multikinase inhibitors of VEGF and TGF beta and uses thereof | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.